The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 30, 2021

Filed:

Dec. 20, 2016
Applicants:

Erik DE Leeuw, Baltimore, MD (US);

Alexander Mackerell, Baltimore, MD (US);

Steven Fletcher, Baltimore, MD (US);

Jamal Chauhan, Baltimore, MD (US);

Inventors:

Erik de Leeuw, Baltimore, MD (US);

Alexander MacKerell, Baltimore, MD (US);

Steven Fletcher, Baltimore, MD (US);

Jamal Chauhan, Baltimore, MD (US);

Assignee:

UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 309/34 (2006.01); A61P 31/04 (2006.01); A61K 31/35 (2006.01); C07D 455/04 (2006.01); C07D 405/06 (2006.01); C07D 403/06 (2006.01); C07D 471/06 (2006.01);
U.S. Cl.
CPC ...
C07D 309/34 (2013.01); A61P 31/04 (2018.01); C07D 403/06 (2013.01); C07D 405/06 (2013.01); C07D 455/04 (2013.01); C07D 471/06 (2013.01);
Abstract

Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compound 6jc48-1 ((E)-2,4-bis(4-bromophenyl)-6-(4-(dimethyl-amino)styryl)pyrylium boron tetrafluoride salt) binds to Lipid II with high affinity, has markedly reduced cytotoxicity than BAS00127538, and retains activity against drug-resistant strains of. It is stable in plasma, has dramatically improved pharmacokinetic and pharmacodynamics properties, and possesses in vivo efficacy in a mouse model of sepsis.


Find Patent Forward Citations

Loading…